The Omicron variant of the coronavirus does not have a negative effect on cardiovascular health in young adults who have been vaccinated, a small study suggests. Additionally, women should not delay routine mammograms after receiving a COVID-19 mRNA vaccine, experts now say.

Drugmakers Pfizer Inc and BioNTech SE said on May 23 that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries.

Inovio Pharmaceuticals announced a leadership change at the helm and the discontinuation of a Phase III COVID-19 vaccine study.

Roche

The fresh blow to Roche’s hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on May 11, but the latest setback is not the end of the road for these oncology treatments, analysts say.

Pfizer Inc.’s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that the transaction may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.

Development of a new cancer treatment pioneered by Roche was thrown into doubt on May 11 when the immunotherapy drug failed to slow progression of lung cancer in a second trial, hitting the Swiss pharmaceutical maker’s shares.

Novavax Inc.’s shares plunged nearly 20 percent in premarket trading on May 10 due to uncertainty over global demand for the company’s COVID-19 vaccine following a slow start to deliveries.

Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.

BioNTech continues to build on the success of the company’s mRNA COVID-19 vaccine co-developed with Pfizer, rapidly expanding its investigational pipeline to include additional infectious diseases and oncology with a first-in-class CAR-T program in solid tumors.